Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 19/20 | 0.78 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.58 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7004870 | 0.89 | PDE5A (0.74) | PDE5APDE3BPDE3AKDM4EHDAC1 | |
| Udenafil SCHEMBL30452348 | 0.88 | PDE5A (1.00) | PDE5AKDM4E | |
| Udenafil SCHEMBL120993 | 0.88 | PDE5A (1.00) | PDE5AKDM4E | |
| SCHEMBL7000981 | 0.87 | KDM4E (0.71) | PDE5AKDM4E | |
| Udenafil SCHEMBL8065455 | 0.87 | PDE5A (0.87) | PDE5AKDM4E | |
| Udenafil SCHEMBL8066470 | 0.87 | PDE5A (0.83) | PDE5APDE3BPDE3AKDM4E | |
| Udenafil SCHEMBL8064505 | 0.87 | PDE5A (0.87) | PDE5APDE3BPDE3AKDM4E | |
| Udenafil SCHEMBL8069104 | 0.87 | PDE5A (0.87) | PDE5APDE3BPDE3AKDM4E | |
| Udenafil SCHEMBL8066483 | 0.87 | PDE5A (0.83) | PDE5APDE3BPDE3AKDM4E | |
| Udenafil SCHEMBL8055433 | 0.85 | PDE5A (0.94) | PDE5AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6844436-B2 | Preparing pyrazolopyrimidinone derivatives for the treatment of impotence | DONG A. PHARM. CO., LTD. (KR) | 2005-01-18 | — | — | US | claimed |
| US-20030176696-A1 | Preparing pyrazolopyrimidinone derivatives for the treatment of impotence | MEZZION PHARMA CO., LTD. (KR) | 2003-09-18 | — | — | US | claimed |
| US-6844436-B2 | Preparing pyrazolopyrimidinone derivatives for the treatment of impotence | DONG A. PHARM. CO., LTD. (KR) | 2005-01-18 | — | — | US | disclosed |
| US-20030176696-A1 | Preparing pyrazolopyrimidinone derivatives for the treatment of impotence | MEZZION PHARMA CO., LTD. (KR) | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176696-A1 | Preparing pyrazolopyrimidinone derivatives for the treatment of impotence | PDE3B, PDE8B, PDE5A | PDE5A 3/4885PDE3B 1/4885PDE3A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.